Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
Summary Background Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane m...
Saved in:
| Published in | The Lancet (British edition) Vol. 377; no. 9762; pp. 321 - 331 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
22.01.2011
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary Background Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). Methods The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35–96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov , NCT00279448 , NCT00032136 , and NCT00036270 ; NTR 267 ; Ethics Commission Trial 27/2001 ; and UMIN , C000000057. Findings 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88–1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Interpretation Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Funding Pfizer. |
|---|---|
| AbstractList | Background: Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). Methods: The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial 27/2001; and UMIN, C000000057. Findings: 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0 super(.97, 95% CI 0) super(.)88-1 super(.08; p=0) super(.)60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Interpretation: Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Funding: Pfizer. Summary Background Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). Methods The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35–96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov , NCT00279448 , NCT00032136 , and NCT00036270 ; NTR 267 ; Ethics Commission Trial 27/2001 ; and UMIN , C000000057. Findings 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88–1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Interpretation Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Funding Pfizer. Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial27/2001; and UMIN, C000000057. 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88-1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Pfizer. BACKGROUNDAromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane).METHODSThe Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial27/2001; and UMIN, C000000057.FINDINGS9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88-1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone.INTERPRETATIONTreatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer.FUNDINGPfizer. BACKGROUND: Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). METHODS: The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35–96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial27/2001; and UMIN, C000000057. FINDINGS: 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88–1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. INTERPRETATION: Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. FUNDING: Pfizer. Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35–96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial 27/2001; and UMIN, C000000057. 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0·97, 95% CI 0·88–1·08; p=0·60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Pfizer. Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer. We therefore compared the long-term effects of exemestane monotherapy with sequential treatment (tamoxifen followed by exemestane). The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial was conducted in hospitals in nine countries. Postmenopausal women (median age 64 years, range 35-96) with hormone-receptor-positive breast cancer were randomly assigned in a 1:1 ratio to open-label exemestane (25 mg once a day, orally) alone or following tamoxifen (20 mg once a day, orally) for 5 years. Randomisation was by use of a computer-generated random permuted block method. The primary endpoint was disease-free survival (DFS) at 5 years. Main analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics Commission Trial 27/2001; and UMIN, C000000057. 9779 patients were assigned to sequential treatment (n=4875) or exemestane alone (n=4904), and 4868 and 4898 were analysed by intention to treat, respectively. 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free at 5 years (hazard ratio 0.97, 95% CI 0.88-1.08; p=0.60). In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]), and endometrial abnormalities (191 [4%] vs 19 [<1%]) than was exemestane alone. Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]), and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone. Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer. Pfizer. |
| Author | Putter, Hein Paridaens, Robert van de Velde, Cornelis JH Smeets, Jan Markopoulos, Christos Nortier, Johan WR Seynaeve, Caroline Hille, Elysee TM Vannetzel, Jean-Michel Hasenburg, Annette Hadji, Peyman Jones, Stephen E Asmar, Lina Rea, Daniel Kieback, Dirk G Bartlett, John MS Hozumi, Yasuo |
| Author_xml | – sequence: 1 fullname: van de Velde, Cornelis JH, Prof – sequence: 2 fullname: Rea, Daniel, MD – sequence: 3 fullname: Seynaeve, Caroline, MD – sequence: 4 fullname: Putter, Hein, Prof – sequence: 5 fullname: Hasenburg, Annette, Prof – sequence: 6 fullname: Vannetzel, Jean-Michel, MD – sequence: 7 fullname: Paridaens, Robert, Prof – sequence: 8 fullname: Markopoulos, Christos, Prof – sequence: 9 fullname: Hozumi, Yasuo, MD – sequence: 10 fullname: Hille, Elysee TM, PhD – sequence: 11 fullname: Kieback, Dirk G, MD – sequence: 12 fullname: Asmar, Lina, PhD – sequence: 13 fullname: Smeets, Jan, BSc – sequence: 14 fullname: Nortier, Johan WR, Prof – sequence: 15 fullname: Hadji, Peyman, Prof – sequence: 16 fullname: Bartlett, John MS, PhD – sequence: 17 fullname: Jones, Stephen E, MD |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23779370$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21247627$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV1rFDEUhoNU7Lb6E9RQENuL0Zwkk0y8UJZSP6DiRVsQvAiZzBnNOjuzJrOl--_NfrhCb3oVODzn4c15j8hBP_RIyHNgb4CBenvFQLJCaaFOgZ0pLoAX8hGZgNSyKKX-fkAme-SQHKU0Y4xJxcon5JADl1pxPSE_ps1seev6kY5uPtyFFnvq-obiHc4xja5HGnqKLnYrWkd0aaTe9R4jPb2-mH49e0cdjXlhmIeEDV38cgmpoGMMrntKHreuS_hs9x6Tm48X1-efi8tvn76cTy8LX1ZyLIDJxjjB69K0RqPRTStBa4688kzWXKtWGSEa5Q1A1WgNXOlG1UaUAMrV4pi83noXcfizzKltDuOx63L6YZlsVSpdATDxMCk1rwSvVCZP7pGzYRn7_I2NzigQJkPlFvJxSCliaxcxzF1cWWB23ZLdtGTXFaxHm5aszHsvdvJlPcdmv_Wvlgy82gEuede1-cI-pP-c0NoIzTL3csu1brDuZ8zMzRVnUDIG3HBVZuLDlsBcwG3AaJMPmAtsQkQ_2mYID4Z9f8_gu9CHHOs3rjDtzwI2ccu2krUD2MYgxV9sPMpf |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1111_ecc_13722 crossref_primary_10_1684_bdc_2011_1533 crossref_primary_10_3390_jpm11080808 crossref_primary_10_1016_j_ygyno_2014_04_060 crossref_primary_10_1007_s00404_013_3069_4 crossref_primary_10_1093_annonc_mdr448 crossref_primary_10_1200_JCO_2012_44_7805 crossref_primary_10_14694_EdBook_AM_2014_34_e16 crossref_primary_10_1016_j_ahj_2023_10_007 crossref_primary_10_2217_bmt_2020_0012 crossref_primary_10_1186_1756_9966_32_89 crossref_primary_10_12968_npre_2013_11_4_200 crossref_primary_10_1200_JCO_2011_36_8993 crossref_primary_10_1016_j_bbcan_2012_03_001 crossref_primary_10_1016_j_molonc_2015_10_010 crossref_primary_10_1093_annonc_mdt195 crossref_primary_10_1007_s12282_017_0794_8 crossref_primary_10_1007_s12094_014_1164_z crossref_primary_10_1097_gme_0b013e318259eaf3 crossref_primary_10_2217_fon_13_120 crossref_primary_10_3390_cancers12113094 crossref_primary_10_1093_jjco_hyy001 crossref_primary_10_1002_cncr_28783 crossref_primary_10_1016_j_clbc_2017_11_006 crossref_primary_10_1016_j_mpmed_2011_09_011 crossref_primary_10_1186_bcr3481 crossref_primary_10_1007_s10549_014_2873_2 crossref_primary_10_1309_AJCP0EN6AQMWETZZ crossref_primary_10_1038_bjc_2013_116 crossref_primary_10_3109_13697137_2011_647839 crossref_primary_10_14694_EdBook_AM_2012_32_87 crossref_primary_10_1007_s10549_018_05086_8 crossref_primary_10_1200_JCO_2012_45_3068 crossref_primary_10_1007_s12282_012_0386_6 crossref_primary_10_1016_S1470_2045_17_30419_9 crossref_primary_10_1016_j_breast_2013_01_007 crossref_primary_10_1517_14740338_2011_567264 crossref_primary_10_1016_j_gamo_2015_11_001 crossref_primary_10_1002_cam4_3095 crossref_primary_10_1007_s11864_018_0541_1 crossref_primary_10_1007_s11883_023_01085_3 crossref_primary_10_2217_ahe_11_85 crossref_primary_10_1055_a_2238_3153 crossref_primary_10_1016_j_breast_2013_02_015 crossref_primary_10_1016_j_currproblcancer_2023_100959 crossref_primary_10_1586_era_12_83 crossref_primary_10_1016_S0140_6736_15_61074_1 crossref_primary_10_1200_JCO_2011_37_3704 crossref_primary_10_1007_s00280_021_04254_w crossref_primary_10_1634_theoncologist_2011_0037 crossref_primary_10_1016_j_bulcan_2020_07_005 crossref_primary_10_1111_ajco_13034 crossref_primary_10_1007_s00761_012_2303_1 crossref_primary_10_1016_j_currproblcancer_2016_09_003 crossref_primary_10_1016_j_ejso_2011_11_010 crossref_primary_10_1016_S0140_6736_15_61206_5 crossref_primary_10_1038_nrclinonc_2015_124 crossref_primary_10_1136_postgradmedj_2016_134417 crossref_primary_10_1007_s10549_016_3985_7 crossref_primary_10_1007_s12013_014_0145_8 crossref_primary_10_1007_s40615_020_00817_4 crossref_primary_10_1016_j_jcrpr_2016_05_002 crossref_primary_10_2217_fon_14_266 crossref_primary_10_1016_j_ctrv_2015_02_004 crossref_primary_10_1016_j_ejca_2013_06_028 crossref_primary_10_1200_JCO_2015_64_3866 crossref_primary_10_1200_JCO_20_02551 crossref_primary_10_1200_JCO_2013_51_5858 crossref_primary_10_1093_jnci_djt026 crossref_primary_10_1007_s10549_018_4785_z crossref_primary_10_1093_annonc_mdw673 crossref_primary_10_1002_ijc_31291 crossref_primary_10_1007_s10549_013_2777_6 crossref_primary_10_1016_j_ejca_2012_12_025 crossref_primary_10_1016_j_thromres_2021_12_025 crossref_primary_10_1158_2159_8290_CD_11_0248 crossref_primary_10_1007_s10549_013_2792_7 crossref_primary_10_1007_s12282_021_01245_w crossref_primary_10_1038_nrclinonc_2012_47 crossref_primary_10_1055_a_2305_1185 crossref_primary_10_1007_s00595_013_0762_7 crossref_primary_10_1200_JCO_18_00307 crossref_primary_10_1016_j_diabres_2018_02_016 crossref_primary_10_1007_s10549_017_4106_y crossref_primary_10_1186_s12885_017_3559_z crossref_primary_10_1002_clc_23114 crossref_primary_10_1007_s10549_013_2573_3 crossref_primary_10_2217_bmt_12_27 crossref_primary_10_1016_j_critrevonc_2012_06_005 crossref_primary_10_1016_j_breast_2013_01_014 crossref_primary_10_1093_annonc_mds204 crossref_primary_10_1002_cpdd_420 crossref_primary_10_1007_s11912_013_0358_9 crossref_primary_10_1016_S1470_2045_18_30116_5 crossref_primary_10_1007_s10549_013_2619_6 crossref_primary_10_3892_ol_2014_1792 crossref_primary_10_1002_14651858_CD011133_pub2 crossref_primary_10_1097_CCO_0000000000000781 crossref_primary_10_1200_JCO_2010_33_7899 crossref_primary_10_1016_j_ygyno_2013_12_029 crossref_primary_10_1002_cncr_27818 crossref_primary_10_1016_j_breast_2016_01_006 crossref_primary_10_1016_j_maturitas_2011_09_006 crossref_primary_10_1200_JCO_2014_55_9591 crossref_primary_10_1007_s10549_012_2028_2 crossref_primary_10_1016_j_critrevonc_2015_01_007 crossref_primary_10_1016_j_ejcsup_2013_07_029 crossref_primary_10_1093_annonc_mdv146 crossref_primary_10_1038_s41467_018_07021_3 crossref_primary_10_1007_s11764_023_01408_y crossref_primary_10_1161_HCG_0000000000000082 crossref_primary_10_1016_j_radonc_2013_08_020 crossref_primary_10_1530_ERC_13_0099 crossref_primary_10_1007_s12325_011_0039_8 crossref_primary_10_1007_s40261_019_00842_0 crossref_primary_10_1155_2023_3614296 crossref_primary_10_1186_s40360_019_0339_1 crossref_primary_10_1007_s00432_013_1551_9 crossref_primary_10_3390_cancers13246375 crossref_primary_10_1007_s40266_020_00748_z crossref_primary_10_1124_jpet_117_240317 crossref_primary_10_1093_jnci_djx134 crossref_primary_10_1038_nrclinonc_2013_174 crossref_primary_10_3389_fonc_2023_1249160 crossref_primary_10_5858_arpa_2014_0599_OA crossref_primary_10_18632_oncotarget_17194 crossref_primary_10_1007_s11523_019_00656_2 crossref_primary_10_1007_s42000_020_00213_x crossref_primary_10_1016_S1470_2045_17_30462_X crossref_primary_10_1200_JCO_21_00311 crossref_primary_10_1200_JCO_2013_53_8272 crossref_primary_10_1007_s40273_023_01277_4 crossref_primary_10_1007_s10549_019_05518_z crossref_primary_10_1056_NEJMoa1103507 crossref_primary_10_1093_jnci_djx141 crossref_primary_10_1016_j_mce_2013_08_001 crossref_primary_10_1016_j_clbc_2024_02_006 crossref_primary_10_1016_j_clbc_2016_07_003 crossref_primary_10_4137_BCBCR_S6234 crossref_primary_10_1056_NEJMoa1404037 crossref_primary_10_1007_s40487_020_00123_3 crossref_primary_10_1210_js_2019_00096 crossref_primary_10_1200_PO_18_00373 crossref_primary_10_1007_s00129_019_4426_6 crossref_primary_10_1371_journal_pone_0155844 crossref_primary_10_1007_s40619_020_00766_4 crossref_primary_10_1016_j_suc_2012_12_002 crossref_primary_10_1007_s12325_011_0017_1 crossref_primary_10_2165_11594170_000000000_00000 crossref_primary_10_4103_ijc_ijc_55_24 crossref_primary_10_1016_j_clbc_2013_10_015 crossref_primary_10_1097_AOG_0b013e31828bf80c crossref_primary_10_1016_j_breast_2011_07_015 crossref_primary_10_4103_2347_5625_212864 crossref_primary_10_1016_j_coemr_2021_03_007 crossref_primary_10_1001_jama_2019_5780 crossref_primary_10_1007_s10269_011_2080_2 crossref_primary_10_1093_jnci_dju051 crossref_primary_10_1016_j_ctrv_2011_07_005 crossref_primary_10_1200_JCO_2013_50_9737 crossref_primary_10_1007_s10549_020_05715_1 crossref_primary_10_1186_s13058_023_01643_2 crossref_primary_10_1200_JCO_2012_46_6599 crossref_primary_10_1007_s10549_020_06092_5 crossref_primary_10_1155_2016_9565873 crossref_primary_10_1007_s11864_013_0263_3 crossref_primary_10_1093_annonc_mds238 crossref_primary_10_1007_s10549_022_06716_y crossref_primary_10_1016_j_breast_2013_07_033 crossref_primary_10_1007_s10269_015_2549_5 crossref_primary_10_1007_s10549_014_2849_2 crossref_primary_10_1016_j_critrevonc_2016_02_008 crossref_primary_10_3109_0284186X_2014_964809 crossref_primary_10_1080_17446651_2016_1216101 crossref_primary_10_1053_j_seminoncol_2020_05_010 crossref_primary_10_1186_bcr3636 crossref_primary_10_1016_j_ejca_2012_07_026 crossref_primary_10_1007_s00404_015_3974_9 crossref_primary_10_1007_s10549_011_1943_y crossref_primary_10_1038_bjc_2014_530 crossref_primary_10_1038_bjc_2013_609 crossref_primary_10_1016_j_critrevonc_2016_02_017 crossref_primary_10_1093_jnci_djr242 crossref_primary_10_3390_cancers14030508 crossref_primary_10_1016_j_jmoldx_2022_04_002 crossref_primary_10_1111_cas_12474 crossref_primary_10_1016_S1470_2045_11_70373_4 crossref_primary_10_1245_s10434_013_3177_1 crossref_primary_10_1016_j_esmoop_2021_100088 crossref_primary_10_1038_s41523_016_0003_5 crossref_primary_10_1093_ckj_sfad195 crossref_primary_10_1016_j_ejca_2018_03_014 crossref_primary_10_1007_s11739_014_1168_2 crossref_primary_10_1093_annonc_mds055 crossref_primary_10_1007_s10549_016_3995_5 crossref_primary_10_3389_fnagi_2022_831807 crossref_primary_10_1530_ERC_17_0416 crossref_primary_10_1007_s10549_014_3155_8 crossref_primary_10_2217_pgs_12_29 crossref_primary_10_1038_s41523_021_00297_7 crossref_primary_10_1634_theoncologist_2018_0010 crossref_primary_10_1016_j_clon_2012_10_007 crossref_primary_10_1186_s13073_017_0446_9 crossref_primary_10_1007_s10549_023_06925_z crossref_primary_10_1007_s11864_019_0646_1 crossref_primary_10_1016_j_eprac_2022_12_003 crossref_primary_10_1200_JCO_19_02427 crossref_primary_10_1007_s10549_016_3874_0 crossref_primary_10_1007_s13126_016_0326_6 crossref_primary_10_1016_S1283_081X_21_45718_8 crossref_primary_10_1016_j_clbc_2021_04_009 crossref_primary_10_1007_s00129_012_3007_8 crossref_primary_10_1016_j_breast_2014_04_002 crossref_primary_10_1007_s10549_022_06714_0 crossref_primary_10_1530_ERC_17_0425 crossref_primary_10_1093_annonc_mds169 crossref_primary_10_1016_j_jchromb_2012_11_015 crossref_primary_10_1016_S0140_6736_11_60073_1 crossref_primary_10_1042_CS20200309 crossref_primary_10_1080_14656566_2024_2340712 crossref_primary_10_1016_j_breast_2015_01_010 crossref_primary_10_1093_jnci_djr302 crossref_primary_10_1016_j_ejca_2015_01_064 crossref_primary_10_1093_annonc_mds290 crossref_primary_10_1093_eurheartj_suaa004 crossref_primary_10_1111_hir_12230 crossref_primary_10_1634_theoncologist_2012_0315 crossref_primary_10_1007_s10549_017_4601_1 crossref_primary_10_1016_j_molonc_2012_02_003 crossref_primary_10_1016_j_breast_2015_07_028 crossref_primary_10_1007_s10549_011_1578_z crossref_primary_10_1007_s12325_021_01924_2 crossref_primary_10_1016_j_critrevonc_2013_05_015 crossref_primary_10_1016_j_jgo_2013_05_006 crossref_primary_10_1016_j_jsbmb_2016_03_019 crossref_primary_10_1007_s10549_015_3269_7 crossref_primary_10_1177_1758834012438214 crossref_primary_10_1016_j_amjopharm_2011_04_010 crossref_primary_10_3390_jcm11113133 crossref_primary_10_3892_ol_2015_3887 crossref_primary_10_1093_jncics_pkad022 crossref_primary_10_1016_j_ahjo_2022_100129 crossref_primary_10_1200_OP_23_00494 crossref_primary_10_1038_s41598_021_82002_z crossref_primary_10_1200_JCO_2011_40_1455 crossref_primary_10_1530_ERC_13_0269 crossref_primary_10_1016_j_ejca_2018_04_009 crossref_primary_10_1634_theoncologist_2016_0033 crossref_primary_10_1200_JCO_2012_42_8896 crossref_primary_10_1016_j_ejca_2017_03_033 crossref_primary_10_1007_s10549_012_2332_x |
| Cites_doi | 10.1200/JCO.2007.14.4659 10.1002/sim.2712 10.2307/2531989 10.1093/annonc/mdp322 10.1158/0008-5472.SABCS-14 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y 10.1200/JCO.2003.04.194 10.1200/JCO.2007.11.9453 10.1093/annonc/mdn545 10.1158/0008-5472.SABCS-81 10.1056/NEJMoa052258 10.1016/S1470-2045(07)70385-6 10.1007/s10549-005-3783-0 10.1200/JCO.2008.21.3553 10.1016/S0140-6736(97)11423-4 10.1056/NEJMoa0810818 10.1002/bjs.6962 10.1200/JCO.2006.08.8617 10.1016/j.ygyno.2010.08.006 10.1200/JCO.2009.23.1274 10.1038/sj.bjc.6605231 10.1056/NEJMoa040331 10.1200/JCO.2009.26.3756 10.3816/CBC.2008.n.065 10.1200/JCO.2007.10.8274 10.1200/JCO.2007.12.9437 10.1016/S0140-6736(07)60200-1 10.1093/annonc/mdn762 |
| ContentType | Journal Article |
| Copyright | Elsevier Ltd 2011 Elsevier Ltd 2015 INIST-CNRS Copyright © 2011 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 22-Jan 28, 2011 |
| Copyright_xml | – notice: Elsevier Ltd – notice: 2011 Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 22-Jan 28, 2011 |
| DBID | FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TT 0TZ 0U~ 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI PSYQQ Q9U S0X 7X8 7T2 7U2 |
| DOI | 10.1016/S0140-6736(10)62312-4 |
| DatabaseName | AGRIS Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef News PRO Pharma and Biotech Premium PRO Global News & ABI/Inform Professional ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts ProQuest Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection ProQuest Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Family Health Database (Proquest) Health & Medical Collection (Alumni Edition) ProQuest Health Management Database PML(ProQuest Medical Library) ProQuest Psychology Database Research Library ProQuest Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Safety Science and Risk |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student News PRO ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection Environmental Sciences and Pollution Management Global News & ABI/Inform Professional Health Research Premium Collection Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts Pharma and Biotech Premium PRO SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic Health & Safety Science Abstracts Safety Science and Risk |
| DatabaseTitleList | Health & Safety Science Abstracts MEDLINE MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 331 |
| ExternalDocumentID | 2291302901 10_1016_S0140_6736_10_62312_4 21247627 23779370 US201500129265 S0140673610623124 1_s2_0_S0140673610623124 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Pfizer. |
| GrantInformation_xml | – fundername: UMIN grantid: C000000057 – fundername: Ethics Commission Trial grantid: 27/2001 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 3V. 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88A 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AACTN AAEDT AAEDW AAEJM AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AAXKI AAXUO AAYOK ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABTAH ABUWG ACGFS ACGOD ACIUM ACPRK ACRLP ACRZS ADBBV ADMUD ADZCM AEKER AENEX AEVXI AFCTW AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AITUG AJJEV AJOXV AJRQY AJUYK AKRWK AKVCP ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AN0 ANZVX AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0L M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PQQKQ PRG PROAC PSQYO PSYQQ Q~Q R2- RIG ROL RPZ S0X SAD SDF SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU HMCUK NHB UKHRP XFK Y6R ZA5 AEQTP FBQ 08R AAUGY AKALU IQODW CGR CUY CVF ECM EIF NPM AAYXX ACRPL CITATION 0TT 0TZ 0U~ 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PQEST PQUKI Q9U 7X8 7T2 7U2 |
| ID | FETCH-LOGICAL-c584t-104d9a32b59f97e97df41772e28c04b276f6933d6c9118d771267d6b935116ab3 |
| IEDL.DBID | 8C1 |
| ISSN | 0140-6736 |
| IngestDate | Tue Nov 26 10:26:07 EST 2024 Wed Dec 04 06:07:05 EST 2024 Fri Nov 08 06:50:58 EST 2024 Fri Dec 06 01:05:23 EST 2024 Sat Sep 28 07:49:43 EDT 2024 Sun Oct 22 16:04:46 EDT 2023 Wed Dec 27 19:15:19 EST 2023 Fri Feb 23 02:18:31 EST 2024 Tue Oct 15 22:55:54 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9762 |
| Keywords | Steroid Antineoplastic agent Phase III trial Breast disease Antiestrogen Adjuvant treatment Antihormone Estrogen synthase Randomization Selective estrogen receptor modulator Clinical trial Mammary gland Non steroid compound Aromatase inhibitor Enzyme Enzyme inhibitor Breast cancer Malignant tumor Exemestane Androstane derivatives Tamoxifene Medicine Mammary gland diseases Early Cancer |
| Language | English |
| License | CC BY 4.0 Copyright © 2011 Elsevier Ltd. All rights reserved. https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c584t-104d9a32b59f97e97df41772e28c04b276f6933d6c9118d771267d6b935116ab3 |
| Notes | http://dx.doi.org/10.1016/S0140-6736(10)62312-4 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 21247627 |
| PQID | 856796139 |
| PQPubID | 40246 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_856781103 proquest_miscellaneous_847283286 proquest_journals_856796139 crossref_primary_10_1016_S0140_6736_10_62312_4 pubmed_primary_21247627 pascalfrancis_primary_23779370 fao_agris_US201500129265 elsevier_sciencedirect_doi_10_1016_S0140_6736_10_62312_4 elsevier_clinicalkeyesjournals_1_s2_0_S0140673610623124 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-22 |
| PublicationDateYYYYMMDD | 2011-01-22 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2011 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Paridaens, Dirix, Beex (bib4) 2008; 26 Coombes, Hall, Gibson (bib13) 2004; 350 Thurlimann, Keshaviah, Coates (bib25) 2005; 353 Hughes-Davies, Caldas, Wishart (bib12) 2009; 101 Kieback, Harbeck, Bauer (bib29) 2010; 119 Jones, Cantrell, Vukelja (bib15) 2007; 25 Pocock, Geller, Tsiatis (bib19) 1987; 43 Bonneterre, Buzdar, Nabholtz (bib2) 2001; 92 Coombes, Kilburn, Snowdon (bib7) 2007; 369 Burstein, Prestrud, Seidenfeld (bib10) 2010; 28 Jakesz R, Gnant M, Griel R, et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10–14, 2008: 14 (abstr). Jones, Stokoe, Sborov (bib31) 2008; 8 Markopoulos, Polychronis, Zobolas (bib27) 2005; 93 (bib17) 2009 (bib1) 1998; 351 Hadji, Ziller, Kieback (bib30) 2009; 20 Schilder, Seynaeve, Beex (bib32) 2010; 28 Mouridsen, Giobbie-Hurder, Goldhirsch (bib11) 2009; 361 Coates, Keshaviah, Thurlimann (bib6) 2007; 25 Goldhirsch, Ingle, Gelber, Coates, Thurlimann, Senn (bib9) 2009; 20 Putter, Fiocco, Geskus (bib20) 2007; 26 Jones, Seynaeve, Hasenburg (bib18) Dowsett, Allred, Knox (bib22) 2008; 26 Markopoulos, Polychronis, Dafni, Koukouras, Zobolas, Tzorakoleftherakis (bib28) 2009; 20 Viale, Regan, Maiorano (bib23) 2007; 25 Bartlett JMS, Brookes CL, Billingham LJ, et al. A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10–14, 2008: 81 (abstr). (bib5) 2008; 9 (bib8) 2010 Mouridsen, Gershanovich, Sun (bib3) 2003; 21 bib16 van Nes, Seynaeve, Jones (bib14) 2010; 97 Dowsett, Cuzick, Ingle (bib21) 2009; 28 21256370 - Lancet. 2011 Jan 22;377(9762):280-1 10.1016/S0140-6736(10)62312-4_bib26 Markopoulos (10.1016/S0140-6736(10)62312-4_bib28) 2009; 20 Hadji (10.1016/S0140-6736(10)62312-4_bib30) 2009; 20 Thurlimann (10.1016/S0140-6736(10)62312-4_bib25) 2005; 353 Schilder (10.1016/S0140-6736(10)62312-4_bib32) 2010; 28 Markopoulos (10.1016/S0140-6736(10)62312-4_bib27) 2005; 93 Mouridsen (10.1016/S0140-6736(10)62312-4_bib3) 2003; 21 Pocock (10.1016/S0140-6736(10)62312-4_bib19) 1987; 43 Putter (10.1016/S0140-6736(10)62312-4_bib20) 2007; 26 Coombes (10.1016/S0140-6736(10)62312-4_bib13) 2004; 350 (10.1016/S0140-6736(10)62312-4_bib5) 2008; 9 Dowsett (10.1016/S0140-6736(10)62312-4_bib21) 2009; 28 Jones (10.1016/S0140-6736(10)62312-4_bib31) 2008; 8 Burstein (10.1016/S0140-6736(10)62312-4_bib10) 2010; 28 Jones (10.1016/S0140-6736(10)62312-4_bib18) van Nes (10.1016/S0140-6736(10)62312-4_bib14) 2010; 97 (10.1016/S0140-6736(10)62312-4_bib1) 1998; 351 Viale (10.1016/S0140-6736(10)62312-4_bib23) 2007; 25 Goldhirsch (10.1016/S0140-6736(10)62312-4_bib9) 2009; 20 Mouridsen (10.1016/S0140-6736(10)62312-4_bib11) 2009; 361 Bonneterre (10.1016/S0140-6736(10)62312-4_bib2) 2001; 92 (10.1016/S0140-6736(10)62312-4_bib8) 2010 Jones (10.1016/S0140-6736(10)62312-4_bib15) 2007; 25 Coombes (10.1016/S0140-6736(10)62312-4_bib7) 2007; 369 Kieback (10.1016/S0140-6736(10)62312-4_bib29) 2010; 119 Paridaens (10.1016/S0140-6736(10)62312-4_bib4) 2008; 26 Coates (10.1016/S0140-6736(10)62312-4_bib6) 2007; 25 Hughes-Davies (10.1016/S0140-6736(10)62312-4_bib12) 2009; 101 Dowsett (10.1016/S0140-6736(10)62312-4_bib22) 2008; 26 10.1016/S0140-6736(10)62312-4_bib24 |
| References_xml | – volume: 9 start-page: 45 year: 2008 end-page: 53 ident: bib5 article-title: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial publication-title: Lancet Oncol – volume: 28 start-page: 509 year: 2009 end-page: 518 ident: bib21 article-title: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen publication-title: J Clin Oncol contributor: fullname: Ingle – volume: 20 start-page: 49 year: 2009 end-page: 55 ident: bib28 article-title: Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy publication-title: Ann Oncol contributor: fullname: Tzorakoleftherakis – ident: bib16 article-title: Common toxicity criteria, version 2.0 – volume: 43 start-page: 487 year: 1987 end-page: 498 ident: bib19 article-title: The analysis of multiple endpoints in clinical trials publication-title: Biometrics contributor: fullname: Tsiatis – volume: 25 start-page: 4765 year: 2007 end-page: 4771 ident: bib15 article-title: Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy publication-title: J Clin Oncol contributor: fullname: Vukelja – volume: 21 start-page: 2101 year: 2003 end-page: 2109 ident: bib3 article-title: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group publication-title: J Clin Oncol contributor: fullname: Sun – volume: 361 start-page: 766 year: 2009 end-page: 776 ident: bib11 article-title: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer publication-title: N Engl J Med contributor: fullname: Goldhirsch – volume: 26 start-page: 4883 year: 2008 end-page: 4890 ident: bib4 article-title: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group publication-title: J Clin Oncol contributor: fullname: Beex – volume: 97 start-page: 671 year: 2010 end-page: 679 ident: bib14 article-title: Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries publication-title: Br J Surg contributor: fullname: Jones – volume: 20 start-page: 203 year: 2009 end-page: 207 ident: bib30 article-title: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study publication-title: Ann Oncol contributor: fullname: Kieback – volume: 8 start-page: 527 year: 2008 end-page: 532 ident: bib31 article-title: The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer publication-title: Clin Breast Cancer contributor: fullname: Sborov – volume: 28 start-page: 3784 year: 2010 end-page: 3796 ident: bib10 article-title: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer publication-title: J Clin Oncol contributor: fullname: Seidenfeld – volume: 350 start-page: 1081 year: 2004 end-page: 1092 ident: bib13 article-title: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer publication-title: N Engl J Med contributor: fullname: Gibson – volume: 351 start-page: 1451 year: 1998 end-page: 1467 ident: bib1 article-title: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group publication-title: Lancet – volume: 93 start-page: 61 year: 2005 end-page: 66 ident: bib27 article-title: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study publication-title: Breast Cancer Res Treat contributor: fullname: Zobolas – volume: 25 start-page: 3846 year: 2007 end-page: 3852 ident: bib23 article-title: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 publication-title: J Clin Oncol contributor: fullname: Maiorano – volume: 353 start-page: 2747 year: 2005 end-page: 2757 ident: bib25 article-title: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer publication-title: N Engl J Med contributor: fullname: Coates – year: 2009 ident: bib17 article-title: Maintenance and support organization introductory guide, version 12.1 – volume: 119 start-page: 500 year: 2010 end-page: 505 ident: bib29 article-title: Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy publication-title: Gynecol Oncol contributor: fullname: Bauer – volume: 25 start-page: 486 year: 2007 end-page: 492 ident: bib6 article-title: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 publication-title: J Clin Oncol contributor: fullname: Thurlimann – year: 2010 ident: bib8 publication-title: NCCN clinical practice guidelines in oncology: breast cancer V.1.2010 – volume: 101 start-page: 875 year: 2009 end-page: 878 ident: bib12 article-title: Tamoxifen: the drug that came in from the cold publication-title: Br J Cancer contributor: fullname: Wishart – volume: 26 start-page: 2389 year: 2007 end-page: 2430 ident: bib20 article-title: Tutorial in biostatistics: competing risks and multi-state models publication-title: Stat Med contributor: fullname: Geskus – ident: bib18 article-title: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. 31st annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, Dec 10–14, 2008: 15 (abstr) contributor: fullname: Hasenburg – volume: 20 start-page: 1319 year: 2009 end-page: 1329 ident: bib9 article-title: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 publication-title: Ann Oncol contributor: fullname: Senn – volume: 28 start-page: 1294 year: 2010 end-page: 1300 ident: bib32 article-title: Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial publication-title: J Clin Oncol contributor: fullname: Beex – volume: 92 start-page: 2247 year: 2001 end-page: 2258 ident: bib2 article-title: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma publication-title: Cancer contributor: fullname: Nabholtz – volume: 26 start-page: 1059 year: 2008 end-page: 1065 ident: bib22 article-title: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial publication-title: J Clin Oncol contributor: fullname: Knox – volume: 369 start-page: 559 year: 2007 end-page: 570 ident: bib7 article-title: Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial publication-title: Lancet contributor: fullname: Snowdon – volume: 26 start-page: 4883 year: 2008 ident: 10.1016/S0140-6736(10)62312-4_bib4 article-title: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.4659 contributor: fullname: Paridaens – volume: 26 start-page: 2389 year: 2007 ident: 10.1016/S0140-6736(10)62312-4_bib20 article-title: Tutorial in biostatistics: competing risks and multi-state models publication-title: Stat Med doi: 10.1002/sim.2712 contributor: fullname: Putter – volume: 43 start-page: 487 year: 1987 ident: 10.1016/S0140-6736(10)62312-4_bib19 article-title: The analysis of multiple endpoints in clinical trials publication-title: Biometrics doi: 10.2307/2531989 contributor: fullname: Pocock – volume: 20 start-page: 1319 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib9 article-title: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 publication-title: Ann Oncol doi: 10.1093/annonc/mdp322 contributor: fullname: Goldhirsch – ident: 10.1016/S0140-6736(10)62312-4_bib26 doi: 10.1158/0008-5472.SABCS-14 – volume: 92 start-page: 2247 year: 2001 ident: 10.1016/S0140-6736(10)62312-4_bib2 article-title: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma publication-title: Cancer doi: 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y contributor: fullname: Bonneterre – volume: 21 start-page: 2101 year: 2003 ident: 10.1016/S0140-6736(10)62312-4_bib3 article-title: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.194 contributor: fullname: Mouridsen – volume: 25 start-page: 3846 year: 2007 ident: 10.1016/S0140-6736(10)62312-4_bib23 article-title: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.9453 contributor: fullname: Viale – volume: 20 start-page: 49 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib28 article-title: Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy publication-title: Ann Oncol doi: 10.1093/annonc/mdn545 contributor: fullname: Markopoulos – year: 2010 ident: 10.1016/S0140-6736(10)62312-4_bib8 – ident: 10.1016/S0140-6736(10)62312-4_bib18 contributor: fullname: Jones – ident: 10.1016/S0140-6736(10)62312-4_bib24 doi: 10.1158/0008-5472.SABCS-81 – volume: 353 start-page: 2747 year: 2005 ident: 10.1016/S0140-6736(10)62312-4_bib25 article-title: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052258 contributor: fullname: Thurlimann – volume: 9 start-page: 45 year: 2008 ident: 10.1016/S0140-6736(10)62312-4_bib5 article-title: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70385-6 – volume: 93 start-page: 61 year: 2005 ident: 10.1016/S0140-6736(10)62312-4_bib27 article-title: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-005-3783-0 contributor: fullname: Markopoulos – volume: 28 start-page: 1294 year: 2010 ident: 10.1016/S0140-6736(10)62312-4_bib32 article-title: Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial publication-title: J Clin Oncol doi: 10.1200/JCO.2008.21.3553 contributor: fullname: Schilder – volume: 351 start-page: 1451 year: 1998 ident: 10.1016/S0140-6736(10)62312-4_bib1 article-title: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group publication-title: Lancet doi: 10.1016/S0140-6736(97)11423-4 – volume: 361 start-page: 766 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib11 article-title: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0810818 contributor: fullname: Mouridsen – volume: 97 start-page: 671 year: 2010 ident: 10.1016/S0140-6736(10)62312-4_bib14 article-title: Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries publication-title: Br J Surg doi: 10.1002/bjs.6962 contributor: fullname: van Nes – volume: 25 start-page: 486 year: 2007 ident: 10.1016/S0140-6736(10)62312-4_bib6 article-title: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.8617 contributor: fullname: Coates – volume: 119 start-page: 500 year: 2010 ident: 10.1016/S0140-6736(10)62312-4_bib29 article-title: Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2010.08.006 contributor: fullname: Kieback – volume: 28 start-page: 509 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib21 article-title: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.1274 contributor: fullname: Dowsett – volume: 101 start-page: 875 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib12 article-title: Tamoxifen: the drug that came in from the cold publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605231 contributor: fullname: Hughes-Davies – volume: 350 start-page: 1081 year: 2004 ident: 10.1016/S0140-6736(10)62312-4_bib13 article-title: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040331 contributor: fullname: Coombes – volume: 28 start-page: 3784 year: 2010 ident: 10.1016/S0140-6736(10)62312-4_bib10 article-title: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.3756 contributor: fullname: Burstein – volume: 8 start-page: 527 year: 2008 ident: 10.1016/S0140-6736(10)62312-4_bib31 article-title: The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer publication-title: Clin Breast Cancer doi: 10.3816/CBC.2008.n.065 contributor: fullname: Jones – volume: 25 start-page: 4765 year: 2007 ident: 10.1016/S0140-6736(10)62312-4_bib15 article-title: Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy publication-title: J Clin Oncol doi: 10.1200/JCO.2007.10.8274 contributor: fullname: Jones – volume: 26 start-page: 1059 year: 2008 ident: 10.1016/S0140-6736(10)62312-4_bib22 article-title: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.9437 contributor: fullname: Dowsett – volume: 369 start-page: 559 year: 2007 ident: 10.1016/S0140-6736(10)62312-4_bib7 article-title: Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(07)60200-1 contributor: fullname: Coombes – volume: 20 start-page: 203 year: 2009 ident: 10.1016/S0140-6736(10)62312-4_bib30 article-title: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study publication-title: Ann Oncol doi: 10.1093/annonc/mdn762 contributor: fullname: Hadji |
| SSID | ssj0004605 |
| Score | 2.5347836 |
| Snippet | Summary Background Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years... Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of tamoxifen to... BACKGROUND: Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2–3 years of... Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to... BACKGROUNDAromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of... Background: Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of... |
| SourceID | proquest crossref pubmed pascalfrancis fao elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 321 |
| SubjectTerms | Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Adult Aged Aged, 80 and over Androstadienes - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Breast cancer breast neoplasms Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Cancer therapies Clinical medicine Data collection Disease Disease-Free Survival Early Diagnosis endometrium Ethics Family medical history Female General aspects Gynecology. Andrology. Obstetrics Hospitals Humans hyperlipidemia Hypertension Internal Medicine long term effects Mammary gland diseases Mammography Medical sciences Meetings Middle Aged musculoskeletal system patients post-menopause Postmenopause Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism safety assessment Side effects survival tamoxifen Tamoxifen - therapeutic use Thromboembolism thrombosis Tumors unspecific monooxygenase women Womens health |
| Title | Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0140673610623124 https://dx.doi.org/10.1016/S0140-6736(10)62312-4 https://www.ncbi.nlm.nih.gov/pubmed/21247627 https://www.proquest.com/docview/856796139 https://search.proquest.com/docview/847283286 https://search.proquest.com/docview/856781103 |
| Volume | 377 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La9wwEBbdBEovpe-4aRcdekgOblayLNm9lG3YEAobSpOFhR6EXm5TiL2NvZCf3xm_QiFJr7JGrxnNfB6NNIR8SK1KlXWz2DlhYpExE1vnXSylMx7wkeetQ395Jk9X4us6XfexOXUfVjnoxFZR-8qhj_woS9HjAXjl8-ZPjEmj8HC1z6AxIbsM7RxeFD9md12LbCPcby_wHJ2PhQdsdggQgPFY3GeaJoWpMGbS1LBsRZfv4n5A2hqmk2fkaY8o6bwTgefkUShfkMfL_sz8Jfkx97-3gJcb2pir6uayCCU1pafhJlwFxIaBXpY04EPH1GKIekMdisI1PbhYzJeHn6ihMBpfgUQETze_wO7RhLbpPl6R1cni4vg07lMqxA6QRgNKV_jcJNymeZGrkCtfCAYAO_DMzYTlShYyTxIvHSjBzCvFuFRe2hzPG6WxyWuyU1Zl2CNU8TQwVXCVFhZTWBuRYquu4MB1401EPg6rqTfdyxn6jpAyKGqXX4uIqGHN9XAtFBRZqPtdVWuma65nHTUSw-8skgJlNlL2wKEDBBrswv863QPuavMTVKpenXN0AKFvjss0ItN_WD7OguMjjYmaRWR_kAE9jnGU04jQ8SswCM9hgKPVFqoIhQmiMvlAFWglA2SWRORNJ1y3vcOEwYKptw_2vk-edN5vFnP-juw019vwHuBTY6dkotZq2m6VKdn9sjj79v0v9QsSUQ |
| link.rule.ids | 314,780,784,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,73745,74014,74302 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELboVgIuiGcbCsUHDu0hNHFiO-GCFrTVAt0VortSJQ6WX4EiNVmarNSfz0ySTYXUlqvj8WvGM1_GYw8hb7mRXBobhdamOkyzWIfGOhsKYbUDfORY69CfzcV0mX4542d9bE7dh1VudGKrqF1l0Ud-lHH0eABe-bD6E2LSKDxc7TNobJFtfDidj8j2x8n82_ebLka2Me7XV3iOTofCgzg6BBAQszC9zThtFbrCqEldw8IVXcaL2yFpa5qOH5NHPaak404InpB7vnxK7s_6U_Nn5MfY_V4DYm5ooy-qq_PCl1SXjvorf-ERHXp6XlKPTx1Tg0HqDbUoDJf0YDEZzw7fU01hNK4CmfCOrn6B5aMJbRN-PCfL48ni0zTskyqEFrBGA2o3dblOmOF5kUufS1ekMUBszzIbpYZJUYg8SZywoAYzJ2XMhHTC5HjiKLRJXpBRWZV-l1DJuI9lwSQvDCax1inHVm3BgO_a6YC826ymWnVvZ6gbgsqgqF1-lQZEbtZcbS6Ggirzdb-vahWrmqmoo0Zi-KFFUqDMBsoeOnSQQIFl-F-nu8BdpX-CUlXLU4YuIPTOMcEDsv8Py4dZMHymMZFRQPY2MqCGMQ6SGhA6fAUG4UkMcLRaQ5VUYoqoTNxRBVrJAJslAdnphOu6d5gw2DD58s7e35AH08XsRJ18nn_dIw87X3gcMvaKjJrLtX8NYKox-_2W-QsMzxRe |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELboVqq4IN4NheIDh_YQNnEcO-GCFthVeeyqol2pEgfLTyhSk6XJSv35jBNvKqS2XB2PH-PxzJfx2IPQm1zxnCudxFpTGdMilbHSRseMaWkAHxnSOfTnC3a0pF_O8rPwpFATwio3OrFT1KbW3kc-LnLv8QC8MnYhKuL40-z96k_sE0j5g9aQTWMLbYNRTMgIbX-YLo6_33RJsot3v77OMz4ZCg_S5BAAQUpiepuh2nKy9hGUsgEmuj77xe3wtDNTs4foQcCXeNILxCN0z1aP0c48nKA_QT8m5vca0HOLW3lRX507W2FZGWyv7IX1SNHi8wpb_-wxVj5gvcXaC8YlPjidTuaH77DEMBpTg3xYg1e_wAriDHfJP56i5Wx6-vEoDgkWYg24owUVTE0pM6Ly0pXcltw4mgLctqTQCVWEM8fKLDNMg0osDOcpYdwwVfrTRyZV9gyNqrqyuwhzktuUO8Jzp3xCa0lz36p2BGRAGhmhtxtuilX_joa4IcAMijr2CxohvuG52FwSBbVmm7DHGpGKhoikp_bE8HPrSYGyGCgDjOjhgQAr8b9Od2F1hfwJClYsT4h3B3lPHWF5hPb_WfJhFsQ_2ZjxJEJ7GxkQwxgHqY0QHr7CAvlTGVjReg1VKPfpogp2RxVopQCclkXoeS9c173DhMGe8Rd39v4a7cBuEd8-L77uofu9WzyNCXmJRu3l2r4CXNWq_bBj_gJ_thiL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+tamoxifen+and+exemestane+in+early+breast+cancer+%28TEAM%29%3A+a+randomised+phase+3+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=van+de+Velde%2C+Cornelis+J+H&rft.au=Rea%2C+Daniel&rft.au=Seynaeve%2C+Caroline&rft.au=Putter%2C+Hein&rft.date=2011-01-22&rft.eissn=1474-547X&rft.volume=377&rft.issue=9762&rft.spage=321&rft.epage=331&rft_id=info:doi/10.1016%2FS0140-6736%2810%2962312-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673611X60038%2Fcov150h.gif |